Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
miércoles, septiembre 23
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Pharming Group
PHAR
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$11.26
0.45
4.16%
al cierre: Sep 22, 5:00 PM EST
$10.91
-0.35
-3.11%
After hour: 8:09 AM EST
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Comparar
Informe de acciones
Pharming Financials
Pharming (PHAR) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Pharming Lowers FY2026 Sales Guidance from $405.000M-$425.000M to $375.000M-$395.000M vs $419.100M Est
Pharming (NASDAQ:PHAR) lowers FY2026 sales outlook from $405.000 million-$425.000 million to $375.000 million-$395.000 million vs $419.100 million estimate.
Benzinga Newsdesk
PRO
Pharming Q2 EPS $0.02, Inline, Sales $90.200M Miss $100.625M Estimate
Pharming (NASDAQ:PHAR) reported quarterly earnings of $0.02 per share which met the analyst consensus estimate. This is a 66.67 percent decrease over earnings of $0.06 per share from the same period last year. The
Benzinga Newsdesk
PRO
Pharming Affirms FY2026 Sales Guidance of $405.000M-$425.000M vs $421.375M Est
Pharming (NASDAQ:PHAR) affirms FY2026 sales outlook from $405.000 million-$425.000 million to $405.000 million-$425.000 million vs $421.375 million estimate.
Benzinga Newsdesk
PRO
Pharming Projects FY2026 Total Revenues Of $405M-$425M With 8%-13% Growth Amid Pipeline Investments And Cost Reductions
For 2026, the Company anticipates: Total revenues between US$405 million and US$425 million (8% to 13% growth), with quarterly fluctuations expected.Total operating expenses between US$330 million and US$335 million
Benzinga Newsdesk
PRO
Pharming Q1 EPS $(0.07) Misses $0.01 Estimate, Sales $72.400M Miss $93.750M Estimate
Pharming (NASDAQ:PHAR) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $0.01 by 800 percent. This is a 68.18 percent increase over losses of $(0.22) per share from the same
Benzinga Newsdesk
Earnings Scheduled For March 12, 2026
Benzinga Insights
Privacy Manager